

PRESS RELEASE

innate pharma

INNATE PHARMA ANNOUNCES THE FIRST HUMAN DOSE FOR IPH 2101 (NN 1975)

Marseilles, February 8, 2007

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, announced today that IPH 2101 (NN 1975), a fully human monoclonal antibody developed by Novo Nordisk A/S in collaboration with Innate Pharma, was administered for the first time in humans (in January 2007), as part of a Phase I clinical trial for patients with acute myeloid leukemia (“AML”).

The trial is being performed at two of the largest cancer clinical research centers in France, the Institut Paoli-Calmettes in Marseilles and the Institut Gustave-Roussy in Paris.

Innate Pharma received an undisclosed payment for this first clinical trial milestone.

About IPH 2101 (NN 1975)

The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of NK cells by a monoclonal antibody which blocks the latter's KIR inhibitory receptors thereby potentiating NK cells anti-cancer action.

Previous observations in a human clinical situation (HLA-mismatched allogeneic bone marrow transplantation) provides a model in which the NK inhibitory receptors are not functional. A therapeutic benefit has been observed in this setting for AML patients having received alloreactive NK cells from unrelated donors, supporting the therapeutic concept.


IPH 2101 (NN 1975) aims at reproducing this effect with a pharmacological agent.

About acute myeloid leukemia (“AML”)

AML is one of the most common types of leukemia among adults in the United States and Europe. 13,410 new cases of AML were diagnosed in the United States in 2006, accounting for less than 1% of all cancers but 30% of all leukemia (source: American Cancer Society, 2007). The incidence of AML is low below the age of 40 but increases progressively with age, from approximately 1 per 100,000 at 40 to more than 15 per 100,000 at 75 and over. The median age for presentation of AML is 65 to 70 years (Source: SEER Cancer Statistics Review, 2003).

The current therapeutic strategy for most patients with AML includes an induction therapy phase and a post-remission therapy phase. Induction therapy (the goal of which is to reduce the leukemia burden in terms of the cell count) corresponds to chemotherapy. One of the post-remission therapies is stem cell transplantation.

Successful treatment is far less common in elderly AML patients than in younger patients. Thus, there is a need in AML for an efficient drug with a better safety profile than existing treatment regimens, especially for elderly patients.




PRESS RELEASE

innate pharma

"We are very excited by this great milestone for our company" said François Romagné, CSO of Innate Pharma. He added: "With its new mechanism of action, this drug candidate could have great potential in the treatment of AML and possibly in other cancer indications. However, it is important to emphasize at this stage that the principal objective of the ongoing AML clinical trial is to assess the compound's safety and tolerance when administered to humans - not to measure its efficacy".

"We continue to be very pleased with the excellent progress in our collaboration with Innate Pharma. Entering into clinical trials with the first ever agent to specifically target NK cells is also a significant milestone for Novo Nordisk A/S" said Mads Krogsgaard Thomsem, CSO of Novo Nordisk A/S.



PRESS RELEASE

innate pharma

About Innate Pharma:

Founded in 1999 and funded by reference venture capitalists up to its IPO on Euronext in Paris in 2006, Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) is a biopharmaceutical company developing first-in-class* drugs targeting innate immunity.

The pioneering work of Innate Pharma's scientific founders and research groups has led to the development of three product platforms (gamma delta T cells, NK cells and TLR), each directly or indirectly validated in clinical oncology settings.

Besides cancer, Innate Pharma's drug candidates have development potential in the treatment of infectious disease and chronic inflammation. The company's most advanced molecule is in Phase II clinical trials in cancer.

With its strong scientific position in innate immunity pharmacology, its robust intellectual property portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing immunotherapeutics market.

Based in Marseilles, France, Innate Pharma had 67 employees as of December 31, 2006.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

For any additional information, please contact:

Innate Pharma

Stéphane Boissel, CFO
Tel. : +33 (0)4 96 19 05 58
stephane.boissel@innate-pharma.fr

Alize Public Relations

Caroline Carmagnol
Tel. : +33 (0)6 64 18 99 59
caroline.carmagnol@wanadoo.fr

* with new mechanisms of action.